Endocrine Abstracts

Introduction: Somatostatin analogues (SSA) represent the main therapeutic option in patients affected with functioning well-differentiated neuroendocrine tumors (NET). However, after a variable time from the start of the therapy tachyphylaxys may cause lack of control of clinical syndrome and progression of the disease.Aim: The aim of this preliminary study was to evaluate efficacy in terms of reduction of circulating markers, control of the clinical syn...